<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00930501</url>
  </required_header>
  <id_info>
    <org_study_id>111222</org_study_id>
    <nct_id>NCT00930501</nct_id>
  </id_info>
  <brief_title>Anti-Mullerian Hormone (AMH) and Antral Follicle Count as Markers of Ovarian Reserve- Prospective Followup of Young Cancer Patients</brief_title>
  <acronym>Ovrescancer</acronym>
  <official_title>Phase 1 Prospective Study of Markers of Ovarian Reserve in Young Female Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hadassah Medical Organization</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hadassah Medical Organization</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      young female cancer patients have improving chances of survival. the main risk is a chronic
      damage to their ovarian reserve. This may lead to future infertility.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      our objective is to prospectively follow patients before and after their cancer treatment.
      this should help us learn of the gonadotoxicity of various treatments as well as be able to
      better consult these and future patients of the need of fertility preservation techniques.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2009</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">December 2011</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Anti mullerian hormone</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>antral follicle count</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FSH</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>inhibin b</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>menstrual history</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>E2 and prog</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>Cancer patients</arm_group_label>
    <description>women 5-45 yr olf pre and post chemotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>blood tests</intervention_name>
    <description>time 0 is pretreatment time 3, 6 , 9, 12 months from the end of chemotherapy</description>
    <arm_group_label>Cancer patients</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      bloods
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        females 5-45 years old
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  all females prior and after chemotherapy

        Exclusion Criteria:

          -  do not consent
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ariel Revel, MD</last_name>
    <phone>97226776424</phone>
    <email>arielr2@hadassah.org.il</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hadassah</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ariel Revel, MD</last_name>
      <phone>97226776424</phone>
      <email>arielr2@hadassah.org.il</email>
    </contact>
    <investigator>
      <last_name>Ariel Revel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>June 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 28, 2009</study_first_submitted>
  <study_first_submitted_qc>June 29, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 30, 2009</study_first_posted>
  <last_update_submitted>June 29, 2009</last_update_submitted>
  <last_update_submitted_qc>June 29, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 30, 2009</last_update_posted>
  <responsible_party>
    <name_title>Ariel Revel, MD</name_title>
    <organization>Hadassah</organization>
  </responsible_party>
  <keyword>chemotherapy</keyword>
  <keyword>cancer</keyword>
  <keyword>AMH</keyword>
  <keyword>gonadotoxicity</keyword>
  <keyword>ovarian reserve</keyword>
  <keyword>patients exposed to chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

